Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Telix also announced updates on its clinical trials and strategic collaborations, including a partnership with Regeneron. The filing outlines expectations for future revenue and R&D expenditures, reflecting the company's ongoing growth strategy.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
- Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
- First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
- Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing
- Notification of cessation of securities - TLX
Later from Telix Pharmaceuticals
- Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
- TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
- Telix H1 2026 Results: Investor Webcast Notification
- Telix to Host R&D Day in New York City on September 22, 2026
- Telix HY26 Appendix 4D and Interim Report
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals